| 2023 | 2022 | ||
| £m | £m | ||
Revenue | 1 | ||
Operating costs before exceptional items | 2 | ( | ( |
Exceptional items | 2 | ( | ( |
Share of profit after tax from joint ventures and associates | 11 | ||
Profits less losses on disposal of non-current assets | |||
Operating profit | |||
Adjusted operating profit | 1 | ||
Profits less losses on disposal of non-current assets | |||
Amortisation of non-operating intangibles | 8 | ( | ( |
Acquired inventory fair value adjustments | 2 | ( | ( |
Transaction costs | 2 | ( | ( |
Exceptional items | 2 | ( | ( |
Profits less losses on sale and closure of businesses | 23 | ( | ( |
Profit before interest | |||
Finance income | 4 | ||
Finance expense | 4 | ( | ( |
Other financial income | 4 | ||
Profit before taxation | |||
Adjusted profit before taxation | |||
Profits less losses on disposal of non-current assets | |||
Amortisation of non-operating intangibles | 8 | ( | ( |
Acquired inventory fair value adjustments | 2 | ( | ( |
Transaction costs | 2 | ( | ( |
Exceptional items | 2 | ( | ( |
Profits less losses on sale and closure of businesses | 23 | ( | ( |
Taxation – UK (excluding tax on exceptional items) | ( | ( | |
– UK (on exceptional items) | |||
– Overseas (excluding tax on exceptional items) | ( | ( | |
– Overseas (on exceptional items) | ( | ||
5 | ( | ( | |
Profit for the period | |||
Attributable to Equity shareholders | |||
Non-controlling interests | |||
Profit for the period | |||
Basic and diluted earnings per ordinary share (pence) | 7 | ||
Dividends per share paid and proposed for the period (pence) | 6 | ||
Special dividend per share proposed for the period (pence) | 6 |
| 2023 | 2022 | ||
| £m | £m | ||
Profit for the period recognised in the income statement | |||
| Other comprehensive income | |||
Remeasurements of defined benefit schemes | 12 | ( | |
Deferred tax associated with defined benefit schemes | ( | ||
Items that will not be reclassified to profit or loss | ( | ||
Effect of movements in foreign exchange | ( | ||
Net gain/(loss) on hedge of net investment in foreign subsidiaries | ( | ||
Net gain on other investments held at fair value through other comprehensive income | |||
Deferred tax associated with movements in foreign exchange | ( | ||
Current tax associated with movements in foreign exchange | |||
Movement in cash flow hedging position | ( | ||
Deferred tax associated with movement in cash flow hedging position | ( | ||
Deferred tax associated with movement in other investments | ( | ||
Share of other comprehensive (loss)/income of joint ventures and associates | ( | ||
Effect of hyperinflationary economies | |||
Items that are or may be subsequently reclassified to profit or loss | ( | ||
Other comprehensive (loss)/income for the period | ( | ||
Total comprehensive income for the period | |||
Attributable to Equity shareholders | |||
Non-controlling interests | |||
Total comprehensive income for the period |
| 2023 | 2022 | ||
| £m | £m | ||
| Non-current assets | |||
Intangible assets | 8 | ||
Property, plant and equipment | 9 | ||
Right-of-use assets | 10 | ||
Investments in joint ventures | 11 | ||
Investments in associates | 11 | ||
Employee benefits assets | 12 | ||
Income tax | 5 | ||
Deferred tax assets | 13 | ||
Other receivables | 14 | ||
Total non-current assets | |||
| Current assets | |||
Assets classified as held for sale | 15 | ||
Inventories | 16 | ||
Biological assets | 17 | ||
Trade and other receivables | 14 | ||
Derivative assets | 26 | ||
Current asset investments | 25 | ||
Income tax | |||
Cash and cash equivalents | 18 | ||
Total current assets | |||
Total assets | |||
| Current liabilities | |||
Liabilities classified as held for sale | 15 | ( | |
Lease liabilities | 10 | ( | ( |
Loans and overdrafts | 19 | ( | ( |
Trade and other payables | 20 | ( | ( |
Derivative liabilities | 26 | ( | ( |
Income tax | ( | ( | |
Provisions | 21 | ( | ( |
Total current liabilities | ( | ( | |
| Non-current liabilities | |||
Lease liabilities | 10 | ( | ( |
Loans | 19 | ( | ( |
Provisions | 21 | ( | ( |
Deferred tax liabilities | 13 | ( | ( |
Employee benefits liabilities | 12 | ( | ( |
Total non-current liabilities | ( | ( | |
Total liabilities | ( | ( | |
Net assets | |||
| Equity | |||
Issued capital | 22 | ||
Other reserves | 22 | ||
Translation reserve | 22 | ( | |
Hedging reserve | 22 | ||
Retained earnings | |||
Total equity attributable to equity shareholders | |||
Non-controlling interests | |||
Total equity | |||
| 2023 | 2022 | ||
| £m | £m | ||
| Cash flow from operating activities | |||
Profit before taxation | |||
Profits less losses on disposal of non-current assets | ( | ( | |
Profits less losses on sale and closure of businesses | |||
Transaction costs | 2 | ||
Finance income | 4 | ( | ( |
Finance expense | 4 | ||
Other financial income | 4 | ( | ( |
Share of profit after tax from joint ventures and associates | 11 | ( | ( |
Amortisation | |||
Depreciation (including of right-of-use assets) | |||
Exceptional items | 2 | ||
Acquired inventory fair value adjustments | |||
Effect of hyperinflationary economies | |||
Net change in the fair value of current biological assets | ( | ( | |
Share-based payment expense | 24 | ||
Pension costs less contributions | ( | ||
Increase in inventories | ( | ( | |
Increase in receivables | ( | ( | |
(Decrease)/increase in payables | ( | ||
Purchases less sales of current biological assets | ( | ( | |
(Decrease)/increase in provisions | ( | ||
Cash generated from operations | |||
Income taxes paid | ( | ( | |
Net cash generated from operating activities | |||
| Cash flow from investing activities | |||
Dividends received from joint ventures and associates | 11 | ||
Purchase of property, plant and equipment | ( | ( | |
Purchase of intangibles | ( | ( | |
Lease incentives received | |||
Sale of property, plant and equipment | |||
Purchase of subsidiaries, joint ventures and associates | 23 | ( | ( |
Sale of subsidiaries, joint ventures and associates | |||
Purchase of other investments | ( | ( | |
Interest received | |||
Net cash used in investing activities | ( | ( | |
| Cash flow from financing activities | |||
Dividends paid to non-controlling interests | ( | ( | |
Dividends paid to equity shareholders | 6 | ( | ( |
Interest paid | ( | ( | |
Repayment of lease liabilities | 25 | ( | ( |
Decrease in short-term loans | 25 | ( | ( |
Increase in long-term loans | 25 | ||
Decrease in current asset investments | 25 | ||
Share buyback | ( | ||
Movement from changes in own shares held | ( | ( | |
Net cash used in financing activities | ( | ( | |
Net decrease in cash and cash equivalents | 25 | ( | ( |
Cash and cash equivalents at the beginning of the period | |||
Effect of movements in foreign exchange | ( | ||
Cash and cash equivalents at the end of the period | 25 |
| Attributable to equity shareholders | |||||||||
| Non- | |||||||||
| Issued | Other | Translation | Hedging | Retained | controlling | Total | |||
| capital | reserves | reserve | reserve | earnings | Total | interests | equity | ||
| Note | £m | £m | £m | £m | £m | £m | £m | £m | |
Balance as at 18 September 2021 | ( | ||||||||
| Total comprehensive income | |||||||||
Profit for the period recognised in the income statement | |||||||||
Remeasurements of defined benefit schemes | 12 | ||||||||
Deferred tax associated with defined benefit schemes | ( | ( | ( | ||||||
Items that will not be reclassified to profit or loss | |||||||||
Effect of movements in foreign exchange | |||||||||
Net loss on hedge of net investment in foreign subsidiaries | ( | ( | ( | ||||||
Net gain on other investments held at fair value through other comprehensive income | |||||||||
Movement in cash flow hedging position | |||||||||
| Deferred tax associated with movement in cash flow | |||||||||
hedging position | ( | ( | ( | ||||||
Deferred tax associated with movement in other investments | ( | ( | ( | ||||||
| Share of other comprehensive income of joint ventures | |||||||||
and associates | |||||||||
Effect of hyperinflationary economies | |||||||||
Items that are or may be subsequently reclassified to profit or loss | |||||||||
Other comprehensive income | |||||||||
Total comprehensive income | |||||||||
| Inventory cash flow hedge movements | |||||||||
| Amounts transferred to cost of inventory | ( | ( | ( | ||||||
Total inventory cash flow hedge movements | ( | ( | ( | ||||||
| Transactions with owners | |||||||||
| Dividends paid to equity shareholders | 6 | ( | ( | ( | |||||
Net movement in own shares held | ( | ( | ( | ||||||
Deferred tax associated with share-based payments | ( | ( | ( | ||||||
Dividends paid to non-controlling interests | ( | ( | |||||||
Total transactions with owners | ( | ( | ( | ( | |||||
Balance as at 17 September 2022 | |||||||||
| Total comprehensive income | |||||||||
| Profit for the period recognised in the income statement | |||||||||
Remeasurements of defined benefit schemes | 12 | ( | ( | ( | |||||
Deferred tax associated with defined benefit schemes | |||||||||
Items that will not be reclassified to profit or loss | ( | ( | ( | ||||||
Effect of movements in foreign exchange | ( | ( | ( | ( | |||||
Net gain on hedge of net investment in foreign subsidiaries | |||||||||
| Deferred tax associated with movements in foreign | |||||||||
exchange | ( | ( | ( | ||||||
| Current tax associated with movements in foreign | |||||||||
exchange | |||||||||
Movement in cash flow hedging position | ( | ( | ( | ||||||
| Deferred tax associated with movement in cash flow | |||||||||
hedging position | |||||||||
| Share of other comprehensive income of joint ventures | |||||||||
and associates | ( | ( | ( | ||||||
Effect of hyperinflationary economies | |||||||||
Items that are or may be subsequently reclassified to profit or loss | ( | ( | ( | ( | ( | ||||
Other comprehensive income | ( | ( | ( | ( | ( | ||||
Total comprehensive income | ( | ( | |||||||
| Inventory cash flow hedge movements | |||||||||
| Amounts transferred to cost of inventory | |||||||||
Total inventory cash flow hedge movements | |||||||||
| Transactions with owners | |||||||||
| Dividends paid to equity shareholders | ( | ( | ( | ||||||
Net movement in own shares held | ( | ( | ( | ||||||
Share buyback | ( | ( | ( | ( | |||||
Deferred tax associated with share-based payments | |||||||||
Dividends paid to non-controlling interests | ( | ( | |||||||
Total transactions with owners | ( | ( | ( | ( | ( | ||||
Balance as at 16 September 2023 | ( | ||||||||